Main Menu

Translational Immunotherapy Team

Professor Alan Melcher's team is looking at ways to activate the immune system to attack cancer using therapeutic viruses. These agents are already approved for clinical use and offer major potential benefits to further improve the promising field of immunotherapy.

Team leader

Professor Alan Melcher

Professor Alan Melcher

Professor of Translational Immunotherapy

Professor Melcher is a clinician scientist studying how to activate the immune system to recognise and attack cancer. In particular, he works on oncolytic, anti-cancer viruses, which work mainly as a type of immunotherapy, and is a specialist in melanoma and head and neck cancer.

ORCID 0000-0002-2042-3380

Team members

 Gabby  Baker
Gabby Baker
Scientific Officer

I am a scientific officer working in the Translational Immunotherapy team. I work with oncolytic viruses and study how they interact with the human immune system to stimulate a response against tumour cells.

 Galabina  Bozhanova
Galabina Bozhanova
PhD Student

I am a final year PhD student working on identifying novel immunotherapy combination treatments for melanoma. My PhD project is focused on combining a small molecule inhibitor of mutant BRAF and oncolytic herpes virus and elucidating the immunological consequences of this therapy using novel mouse models and in vitro tools. The findings of my PhD will be used to inform future clinical trials with oncolytic viruses.

Dr Edward Armstrong
Clinical Research Fellow
Dr Matthew Chiu
Clinical Research Fellow
Dr Shane Foo
Dr Shane Foo
Senior Scientific Officer
Lorna Grove
Higher Scientific Officer
Dr Vicki Jennings
Post-doctoral Researcher
David Mansfield
Higher Scientific Officer
Dr Malin Pedersen
Staff Scientist